Tag: Antibody Drug

Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates (ADCs). What is the focus of the agreement: Under the agreement, Ambrx and NovoCodex will join forces to continue the development of ARX305, an Ambrx enabled ADC for the treatment of CD70

While there are close to 200 ADCs in various stages of development, the market field is currently going through a gradual transition, shifting from relying on conventional technologies to newer approaches for generating ADCs. The ‘Antibody Drug Conjugates Market (4th Edition), 2017-2030’ report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion

Certain steps of antibody drug discovery require advanced expertise, and companies offering these specialized services have attracted significant attention of drug / therapy developers. Two such specific services are to reduce antibody immunogenicity (humanization) and enhance its affinity (affinity maturation). The ‘Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030’ report provides a comprehensive view on the current landscape and the